Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interleukin-2 binds to ganglioside GD(1b)
Autore:
Ravindranath, MH; Gonzales, A; Soh, D; Nishimoto, K; Tam, WY; Bilchik, A; Morton, DL; ODay, S;
Indirizzi:
John Wayne Canc Inst, Lab GlycoImmunotherapy, Santa Monica, CA 90404 USA John Wayne Canc Inst Santa Monica CA USA 90404 Santa Monica, CA 90404 USA
Titolo Testata:
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
fascicolo: 2, volume: 283, anno: 2001,
pagine: 369 - 373
SICI:
0006-291X(20010504)283:2<369:IBTGG>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
WHEAT-GERM-AGGLUTININ; SIALIC-ACID; SELECTIVE MODULATION; LYMPHOCYTES-T; SERUM; MELANOMA; CD4; SPECIFICITY; EXPRESSION; RECEPTOR;
Keywords:
gangliosides; GD(1b); interleukin-2 (IL-2); melanoma; tumor biopsy; IL-2-GD(1b) interaction; solid-matrix immunoassay;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Ravindranath, MH John Wayne Canc Inst, Lab GlycoImmunotherapy, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA John Wayne Canc Inst 2200 Santa Monica Blvd Santa Monica CA USA 90404
Citazione:
M.H. Ravindranath et al., "Interleukin-2 binds to ganglioside GD(1b)", BIOC BIOP R, 283(2), 2001, pp. 369-373

Abstract

We have developed a solid matrix immunoassay to determine the binding of interleukin-2 (IL-2) to specific gangliosides. The assay establishes that recombinant human IL-2 binds to ganglioside GD(1b) but not to any other gangliosides (GM(1), GM(2), GM(3), GD(1a), GD(2), GD(3), and GT(1b)). The binding varies with the ratio of GD1b and IL-2. This assay enables distinguishingthe nature of the sugar moiety of the ganglioside recognized by IL-2 and establishes the dosimetry of the ganglioside-IL-2 interaction. Since rIL-2 is administered systematically into stage IV melanoma patients, we have examined 45 tumor biopsies for GD(1b) content. The incidence of GD(1b) in tumorbiopsies is 51%. We postulate that GD(1b) associated on the tumor or in the circulation of cancer patients may bind to rIL-2 and prevent the availability of rIL-2 to augment antitumor-immune response. (C) 2001 Academic Press.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 16:30:36